Phaseline

Companies › Angitia Biopharmaceuticals Guangzhou

Angitia Biopharmaceuticals Guangzhou: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AGA2115–Phase 2Osteogenesis Imperfecta (OI)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07557446AGA2115Phase 2Osteogenesis Imperfecta (OI)OtherApr 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Angitia Zynerba Pharmaceuticals Nocion Therapeutics Next Life Sciences Aelis Farma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.